<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Lupus" post="Sci MedLupus Sci MedlupusscimedlupusLupus Science &amp;amp; Medicine2053-8790BMJ Publishing GroupBMA"/>
 <result pre="Impact of COVID-19 pandemic on SLE: beyond the risk of" exact="infection" post="http://orcid.org/0000-0002-3732-8662HorisbergerAliceMoiLaurahttp://orcid.org/0000-0002-0446-9741RibiCamillohttp://orcid.org/0000-0002-6605-1498ComteDenis[], Service of Immunology and Allergy, Departement de medecineCentre"/>
 <result pre="changes made indicated, and the use is non-commercial. See:Â http://creativecommons.org/licenses/by-nc/4.0/.lupus-2020-000408.pdf" exact="lupus erythematosus," post="systemic antirheumatic agents interferon type I Dear editor, The"/>
 <result pre="indicated, and the use is non-commercial. See:Â http://creativecommons.org/licenses/by-nc/4.0/.lupus-2020-000408.pdf lupus erythematosus," exact="systemic" post="antirheumatic agents interferon type I Dear editor, The rapidly"/>
 <result pre="is non-commercial. See:Â http://creativecommons.org/licenses/by-nc/4.0/.lupus-2020-000408.pdf lupus erythematosus, systemic antirheumatic agents interferon" exact="type I" post="Dear editor, The rapidly expanding coronavirus disease 2019 (COVID-19)"/>
 <result pre="agents interferon type I Dear editor, The rapidly expanding coronavirus" exact="disease" post="2019 (COVID-19) is a global health challenge and a"/>
 <result pre="(COVID-19) is a global health challenge and a source of" exact="anxiety" post="amplified by the constant news stream. The mortality rate"/>
 <result pre="in healthcare systems around the world. The occurrence of severe" exact="acute" post="respiratory distress syndrome (ARDS) and mortality are increased in"/>
 <result pre="healthcare systems around the world. The occurrence of severe acute" exact="respiratory" post="distress syndrome (ARDS) and mortality are increased in the"/>
 <result pre="around the world. The occurrence of severe acute respiratory distress" exact="syndrome" post="(ARDS) and mortality are increased in the elderly and"/>
 <result pre="the elderly and in patients with underlying conditions such as" exact="cardiovascular disease" post="and chronic respiratory conditions. To date, neither autoimmune diseases"/>
 <result pre="elderly and in patients with underlying conditions such as cardiovascular" exact="disease" post="and chronic respiratory conditions. To date, neither autoimmune diseases"/>
 <result pre="in patients with underlying conditions such as cardiovascular disease and" exact="chronic" post="respiratory conditions. To date, neither autoimmune diseases nor immunosuppressants"/>
 <result pre="patients with underlying conditions such as cardiovascular disease and chronic" exact="respiratory" post="conditions. To date, neither autoimmune diseases nor immunosuppressants appear"/>
 <result pre="as cardiovascular disease and chronic respiratory conditions. To date, neither" exact="autoimmune diseases" post="nor immunosuppressants appear to be risk factors for serious"/>
 <result pre="standards of care for patients with SLE. SLE is an" exact="autoimmune disease" post="prone to flare-ups that are linked to significant morbimortality."/>
 <result pre="of care for patients with SLE. SLE is an autoimmune" exact="disease" post="prone to flare-ups that are linked to significant morbimortality."/>
 <result pre="prone to flare-ups that are linked to significant morbimortality. Immunosuppression-related" exact="infections" post="are one of the leading causes of premature death"/>
 <result pre="However, there are currently no data to support a higher" exact="infection" post="rate, an increased risk of ARDS or other serious"/>
 <result pre="Current knowledge of the immunopathology of COVID-19 is far too" exact="limited" post="to draw definitive conclusions, but certain hypotheses can be"/>
 <result pre="characterised by a cytokine storm with features of macrophage activation" exact="syndrome" post="(MAS) and cytokine-release syndrome (CRS).2 There is evidence showing"/>
 <result pre="storm with features of macrophage activation syndrome (MAS) and cytokine-release" exact="syndrome" post="(CRS).2 There is evidence showing that immunosuppressants and, in"/>
 <result pre="inadequate inflammatory response with immunosuppressants to prevent ARDS in COVID-19." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the ACE"/>
 <result pre="inflammatory response with immunosuppressants to prevent ARDS in COVID-19. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the ACE 2"/>
 <result pre="response with immunosuppressants to prevent ARDS in COVID-19. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) uses the ACE 2 as"/>
 <result pre="with immunosuppressants to prevent ARDS in COVID-19. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) uses the ACE 2 as a"/>
 <result pre="SLE compared with healthy controls.4 Data on ACE2 expression in" exact="pulmonary" post="epithelial cells of patients with SLE or on ACE2"/>
 <result pre="compared with healthy controls.4 Data on ACE2 expression in pulmonary" exact="epithelial" post="cells of patients with SLE or on ACE2 gene"/>
 <result pre="or on ACE2 gene polymorphisms in this population are lacking." exact="Type 1" post="interferons (IFNs) are cytokines that play a key role"/>
 <result pre="in antiviral immunity and include among others IFN-Î± and IFN-Î²." exact="Type 1" post="IFN interfere with coronavirus replication in vitro. SARS-CoV, and"/>
 <result pre="the hostâ€™s antiviral signalling pathways, resulting in decreased production of" exact="type I" post="IFN.5 The efficacy and safety of IFN-Î²1 in COVID-19"/>
 <result pre="evaluated as part of the â€˜Solidarityâ€™ clinical trial. Overexpression of" exact="type I" post="IFN is one of the characteristics of SLE and"/>
 <result pre="environmental factors. One may hypothesise that the increased bioavailability of" exact="type 1" post="IFN in SLE promotes host defenses against SARS-CoV2 infection"/>
 <result pre="type 1 IFN in SLE promotes host defenses against SARS-CoV2" exact="infection" post="and provide some degree of protection against severe COVID-19"/>
 <result pre="a potential adjunct treatment for patients with COVID-19 infection. Small" exact="uncontrolled" post="or poorly controlled clinical trials have shown an antiviral"/>
 <result pre="drugs have been proven for a long time. Since only" exact="limited" post="data support the use of these drugs in COVID-19,"/>
 <result pre="clinical trials and for patients with SLE or with other" exact="rheumatic" post="diseases.6 During the current COVID-19 pandemic, strict measures of"/>
 <result pre="regular monitoring should be maintained for the early detection of" exact="disease" post="flare-up.7 With the aim to reduce contact exposure, telephonic"/>
 <result pre="contact exposure, telephonic visits are a reasonable first-step screening for" exact="stable" post="patients, nevertheless face-to-face visit should not be precluded for"/>
 <result pre="visit should not be precluded for SLE patients with active" exact="disease" post="potentially requiring therapeutic changes. COVID-19 pandemic is changing our"/>
 <result pre="changing our approach to clinical surveillance and management. In the" exact="absence of" post="recommendations, we underline the importance to adapt the medical"/>
 <result pre="Apr 2020]. 2GuanW-jie, NiZ-yi, HuY, et al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med202010.1056/NEJMoa2002032 3RuscittiP, CiprianiP,"/>
 <result pre="CiprianiP, Di BenedettoP, et al.Advances in immunopathogenesis of macrophage activation" exact="syndrome" post="during rheumatic inflammatory diseases: toward new therapeutic targets?Expert Rev"/>
 <result pre="BenedettoP, et al.Advances in immunopathogenesis of macrophage activation syndrome during" exact="rheumatic" post="inflammatory diseases: toward new therapeutic targets?Expert Rev Clin Immunol2017;13:1041â€&quot;7."/>
 <result pre="interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in" exact="lupus" post="patients. Clin Immunol2020;215:108410. 10.1016/j.clim.2020.10841032276140 5de WitE, van DoremalenN, FalzaranoD,"/>
 <result pre="ahead of print: 31 Mar 2020]. 7DÃ¶rnerT, FurieRNovel paradigms in" exact="systemic" post="lupus erythematosus. Lancet2019;393:2344â€&quot;58. 10.1016/S0140-6736(19)30546-X31180031"/>
 <result pre="of print: 31 Mar 2020]. 7DÃ¶rnerT, FurieRNovel paradigms in systemic" exact="lupus erythematosus." post="Lancet2019;393:2344â€&quot;58. 10.1016/S0140-6736(19)30546-X31180031"/>
</results>
